The Munich-based corporate financing specialist welcomes yet another highly regarded authority to its Life Sciences Advisory Board. Munich, December 15, 2020
The newest member of the Life Sciences Advisory Board at FCF Fox Corporate Finance GmbH (“FCF”) is renowned expert Dr. Axel Polack, who will give the corporate finance specialist valuable support and guidance regarding the life sciences ecosystem.
As CEO of the consulting firm Polack Holding GmbH, Dr. Axel Polack has helped several up-and-coming life sciences entrepreneurs to commercialize their inventions by creating new start-ups or securing angel investors. Dr. Polack has had a successful career as a scientist in addition to his 20 years in venture capital, serving as General Partner for both TVM Capital and the Joint Polish Investment Fund.
Dr. Mathias Schott, the head of Life Sciences at FCF, is delighted with the new addition: “Dr. Axel Polack has an impressive track record in life sciences, and it will be an honor to have such an accomplished expert on our team.”
Since 2018, the Life Sciences Advisory Board has played a key role in FCF’s corporate strategy when it comes to life sciences financing, focusing on highly innovative companies in the Biotech and Medtech arenas. FCF founding partner and CEO Arno Fuchs on the future of the board: “Our aim is to mobilize a team of advisors with top-class scientific, operational and strategic expertise in the life sciences space, not only on the German market, but also across Europe.”
ABOUT FCF FOX CORPORATE FINANCE
FCF is a specialized Investment Bank and Financing Specialist, advising public and private small/mid-market companies in the German speaking regions.FCF focuses on four primary client segments:
- MidCap: Medium-sized companies with sustainable business models in typical “Mittelstand” industries, such as industrial products and machinery, automotive, communications, logistics, and consumer products
- SmallCap / Growth: Companies with revenues between €20 and €100 million and high / above average growth rates
- DeepTech: R&D-driven companies in technology sectors, entering the commercialization stage with initial fast-growing revenues
- Life Sciences: Highly innovative companies focusing on the development of cutting-edge biotechnology, med-tech, health-tech and pharmaceuticals solutions
FCF structures, arranges and places equity and debt capital transactions and supports its clients’ growth, IPO/Pre-IPO, acquisition and standard balance sheet (re-)financing strategies.
Founded in 2005 and headquartered in Munich, FCF has direct relationships and works with all leading German, European and international financiers, lenders and investment houses addressing German small/mid-cap companies.